DNA Methylation and Its Impact on Chronic Myelogenous Leukemia
Author Information
Author(s): Jelinek Jaroslav, Gharibyan Vazganush, Estecio Marcos R. H., Kondo Kimie, He Rong, Chung Woonbok, Lu Yue, Zhang Nianxiang, Liang Shoudan, Kantarjian Hagop M., Cortes Jorge E., Issa Jean-Pierre J.
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
The study aims to elucidate the role of DNA methylation in chronic myelogenous leukemia (CML) and its association with disease progression and imatinib resistance.
Conclusion
Aberrant DNA methylation is associated with disease progression in CML and may serve as a marker for imatinib resistance.
Supporting Evidence
- Hypermethylation was observed in 4,138 of 27,890 total CpG sites analyzed.
- Patients resistant or intolerant to imatinib had a higher average number of methylated genes.
- Hypermethylation of PDLIM4 was associated with shortened survival independently of CML stage.
Takeaway
This study found that changes in DNA can affect how chronic myelogenous leukemia gets worse and how well patients respond to treatment.
Methodology
The study analyzed DNA methylation in 120 CML patients using bisulfite pyrosequencing and compared methylation levels across different disease phases and treatment responses.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective analysis of data.
Limitations
The study is limited by the retrospective nature and the small sample size for certain subgroups.
Participant Demographics
The median age of participants was 50 years, with 65% being male.
Statistical Information
P-Value
0.0004
Confidence Interval
95% confidence interval 2.3 to 3.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website